In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
14 authors.
Xueying YuanDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-6242-7630 Diego A PedrozaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-7355-2952 Fengshuo LiuLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Kang LeInstitute for Applied Cancer Science (IACS), the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0004-0279-7815 Alex J SmithDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Sebastian J CalderonDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Nadia LieuDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Michael J SothInstitute for Applied Cancer Science (IACS), the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Philip JonesInstitute for Applied Cancer Science (IACS), the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiang H-F ZhangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-5674-8670 Jeffrey M RosenDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-6637-844X Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9MTherapeutic Targeting of Breast Cancer Tumor Initiating CellsR01CA148761 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2010 to 2025
$6.5MOsteoclast-Independent Mechanisms of Early-Stage Bone Colonization of Breast CancerR01CA183878 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, XIANG · 2014 to 2024
$3.5MUnveiling the mechanisms underlying secondary metastasis and possible therapeutic windowsR01CA251950 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, XIANG · 2020 to 2024
$2.6MOsteogenic Niche Biology in Progression and Endocrine Resistance of Bone MetastasesR01CA221946 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ROWLEY, DAVID R · 2018 to 2022
$2.4MRewired Metabolism Regulates Vessel Normalization and ImmunosuppressionR01CA227904 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SREEKUMAR, ARUN, ZHANG, XIANG · 2019 to 2023
$2.3MBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kAcquisition of 10X Genomics Chromium Instrument to Accelerate Genomic and Single Cell Transcriptomic ResearchS10OD025240 · OD · BAYLOR COLLEGE OF MEDICINE · PI DODDAPANENI, HARSHA VARDHAN · 2018 to 2018
$125kNCI NIH HHS P30 CA125123NCI NIH HHS R01 CA148761NCI NIH HHS R01 CA183878NCI NIH HHS R01 CA221946NCI NIH HHS R01 CA227904NCI NIH HHS R01 CA251950NCRR NIH HHS S10 RR024574NIH HHS S10 OD025240
6 · The paper itselfAbstract
Tumor-associated neutrophils (TANs) have been shown to promote immunosuppression and tumor progression, and a high TAN frequency predicts poor prognosis in triple-negative breast cancer (TNBC). Dysregulation of CREB binding protein (CBP)/P300 function has been observed with multiple cancer types. The bromodomain (BRD) of CBP/P300 has been shown to regulate its activity. In this study, we found that IACS-70654, a novel and selective CBP/P300 BRD inhibitor, reduced TANs and inhibited the growth of neutrophil-enriched TNBC models. In the bone marrow, CBP/P300 BRD inhibition reduced the tumor-driven abnormal differentiation and proliferation of neutrophil progenitors. Inhibition of CBP/P300 BRD also stimulated the immune response by inducing an IFN response and MHCI expression in tumor cells and increasing tumor-infiltrated CTLs. Moreover, IACS-70654 improved the response of a neutrophil-enriched TNBC model to docetaxel and immune checkpoint blockade. This provides a rationale for combining a CBP/P300 BRD inhibitor with standard-of-care therapies in future clinical trials for neutrophil-enriched TNBC.
Identifiers
PMID38712292
PMCPMC11071628
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390